MannKind Corp (MNKD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
MannKind Corp stock (MNKD) is currently trading at $2.29. MannKind Corp PE ratio is 123.50. MannKind Corp PS ratio (Price-to-Sales) is 2.18. Analyst consensus price target for MNKD is $7.50. WallStSmart rates MNKD as Sell.
- MNKD PE ratio analysis and historical PE chart
- MNKD PS ratio (Price-to-Sales) history and trend
- MNKD intrinsic value — DCF, Graham Number, EPV models
- MNKD stock price prediction 2025 2026 2027 2028 2029 2030
- MNKD fair value vs current price
- MNKD insider transactions and insider buying
- Is MNKD undervalued or overvalued?
- MannKind Corp financial analysis — revenue, earnings, cash flow
- MNKD Piotroski F-Score and Altman Z-Score
- MNKD analyst price target and Smart Rating
MannKind Corp
📊 No data available
Try selecting a different time range
MNKD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · MannKind Corp (MNKD)
MNKD trades 4000% above its Graham fair value of $0.14, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
MannKind Corp (MNKD) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and operating margin. Significant fundamental concerns warrant caution or avoidance.
MannKind Corp (MNKD) Key Strengths (2)
Revenue surging 45.80% year-over-year
59.47% held by institutions, strong professional interest
Supporting Valuation Data
MannKind Corp (MNKD) Areas to Watch (7)
Losing money on operations
Earnings declining -34.90%, profits shrinking
Very expensive relative to growth, significant premium
Very expensive at 187.8x book value
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.18x sales
Supporting Valuation Data
MannKind Corp (MNKD) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 45.80%.
The Bear Case
The primary concerns are Operating Margin, EPS Growth, PEG Ratio. Some valuation metrics including PEG Ratio (4.39), Price/Sales (2.18), Price/Book (187.85) suggest expensive pricing. Growth concerns include EPS Growth at -34.90%, which may limit upside. Profitability pressure is visible in Operating Margin at -6.87%, Profit Margin at 1.68%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -6.87% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 45.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MNKD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MNKD's Price-to-Sales ratio of 2.18x trades at a deep discount to its historical average of 333.77x (2th percentile). The current valuation is 100% below its historical high of 9740.39x set in Nov 2011, and 142% above its historical low of 0.9x in Feb 2017. Over the past 12 months, the PS ratio has compressed from ~2.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for MannKind Corp (MNKD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
MannKind Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 349M with 46% growth year-over-year. Profit margins are strong at 168.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 46% YoY, reaching 349M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can MannKind Corp maintain 46%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 123.5x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact MannKind Corp.
Bottom Line
MannKind Corp offers an attractive blend of growth (46% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(15 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CASTAGNA, MICHAEL Director, Chief Executive Officer | Buy | +100,000 |
| Insider | Type | Shares |
|---|---|---|
TROSS, STUART A Chief People & Workpl Officer | Sell | -47,006 |
Data sourced from SEC Form 4 filings
Last updated: 8:25:24 AM
About MannKind Corp(MNKD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.